SCHEMBL1007246

SCHEMBL1007246

NC(=O)c1c(NC(=O)CCl)sc2c1CCCC2

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.75
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
CYP1A2 P05177 1/20 0.72
CYP2C19 P33261 1/20 0.72
ALDH1A1 P00352 5/20 0.71
TSHR P16473 4/20 0.71
LMNA P02545 3/20 0.71
MAPT P10636 3/20 0.71
GFER P55789 1/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
KDM4E B2RXH2 2/20 0.71
MAPK1 P28482 1/20 0.71
HPGD P15428 4/20 0.68
GAA P10253 1/20 0.68
HSD17B10 Q99714 2/20 0.65
RAB9A P51151 1/20 0.64
MAPK10 P53779 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
CDK2 P24941 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31562921 0.97 KDM4E (0.75) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL3453230 0.89 FLT3 (0.71) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL6246452 0.87 GAA (0.67) FLT3MEN1KMT2AALDH1A1LMNA
SCHEMBL4135422 0.86 HPGD (0.83) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5453467 0.86 FLT3 (1.00) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL3453042 0.86 FLT3 (0.75) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL3914847 0.84 FLT3 (1.00) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5455950 0.83 HPGD (0.83) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5465217 0.83 ALDH1A1 (0.81) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5451052 0.83 ALDH1A1 (1.00) FLT3MEN1KMT2ACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2806875-B1 PROTEASOME ACTIVITY MODULATING COMPOUNDS PROTEOSTASIS THERAPEUTICS INC (US) 2017-07-19 EP disclosed
US-9399647-B2 Proteasome activity modulating compounds PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-07-26 US disclosed
US-20150166565-A1 PROTEASOME ACTIVITY MODULATING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. 2015-06-18 US disclosed
EP-2806875-A1 PROTEASOME ACTIVITY MODULATING COMPOUNDS Proteostasis Therapeutics, Inc. (US) 2014-12-03 EP disclosed
WO-2013112651-A2 PROTEASOME ACTIVITY MODULATING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. (US) 2013-08-01 WO disclosed
WO-2013112706-A1 PROTEASOME ACTIVITY MODULATING COMPOUNDS PROTEOSTASIS THERAPEUTICS, INC. (US) 2013-08-01 WO disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2005044008-A2 2 -AMINOTHIOPHENE COMPOUNDS AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166565-A1 PROTEASOME ACTIVITY MODULATING COMPOUNDS PSMG3, PSMB1, PSMB11 FLT3 4541/4885MEN1 3617/4885KMT2A 2606/4885
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 FLT3 136/4885MEN1 1454/4885KMT2A 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.